“I like to label us as ‘the little mouse that roared,’” begins John Didsbury, Ph.D., and Chief Executive Officer at T3D Therapeutics, a clinical stage drug development company engaged in the development of T3D-959, a new orally administered metabolic-focused treatment for Alzheimer’s disease in Raleigh, NC.  With more than 5 million Americans living with Alzheimer’s […]